Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
article
OA: closed
CC0
⤵ 11 in-corpus citations
AI-generated summary
Nafarelin treatment for endometriosis reduced bone mineral density, which did not fully recover to baseline levels six months after drug cessation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY OBJECTIVE: To determine the reversibility of bone mineral density after the cessation of GnRH agonist treatment for endometriosis. DESIGN: Longitudinal trial with 6-month treatment period and 6-month follow-up. PATIENTS: 28 Japanese premenopausal women with endometriosis. INTERVENTIONS: Daily dose of 400 micrograms nafarelin was administered for 6 months. MEASUREMENT AND MAIN RESULTS: The spine bone mineral density was measured by dual energy X-ray absorptiometry, and blood and urinary bone metabolic parameters were analyzed. The decrease of lumbar bone mineral density, which took place during treatment, continued during the first 3 months after the cessation of treatment and did not return to the initial baseline level even at 6 months after the withdrawal of treatment. The biochemical parameters, which showed a state of enhanced bone turnover during nafarelin treatment, almost returned to the pretreatment level 6 months after the termination of treatment. CONCLUSION: These results indicate that relatively long period of bone metabolic change might be required to alter the actual bone mineral density after GnRH analog administration.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (9)
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. via openalex
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma via openalex
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN via openalex
- W2129449855 via openalex
- W2287757320 via openalex
- W2055260481 via openalex
Cited by (11)
- The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis 2022
- Medical Treatment in Endometriosis 2012
- Long-term fracture risk among women with proven endometriosis 2006
- Prolonged GnRH Agonist and Add-Back Therapy for Symptomatic Endometriosis 2002
- Endometriosis: current concepts and therapy 2002
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 2002
- Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy) 2000
- Women of Reproductive Age with Endometriosis are Not Osteopenic 1998
- The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover 1998
Source provenance
- europepmc
- last seen: 2026-06-21T06:12:49.409960+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:08.331550+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK